Table 2.
Significant activation when testing for placebo analgesia effects in unpleasant touch and pain in bilateral IC and aMCC
| PFWE-corr. | k | t-value | x,y,z (MNI) | Anatomical region |
|---|---|---|---|---|
| (A) Unpleasant touch placebo effects: | ||||
| Self-unpleasant touch: controls > placebo | ||||
| <0.001 | 80 | 5.29 | 38 –20 10 | Right posterior IC |
| Other-unpleasant touch: controls > placebo | ||||
| 0.008 | 56 | 4.48 | 36 28 6 | Right anterior IC |
| (B) Pain placebo effects: | ||||
| Self-pain: controls > placebo | ||||
| <0.001 | 590 | 5.25 | −8 16 30 | aMCC |
| <0.001 | 463 | 6.82 | −26 26 8 | Left anterior IC |
| <0.001 | 307 | 6.44 | 40 14 4 | Right anterior IC |
| <0.001 | 43 | 5.89 | 30 28 8 | Right anterior IC |
| 0.006 | 28 | 4.57 | 32 –18 16 | Right posterior IC |
| 0.007 | 51 | 4.55 | 38 –14 0 | Right posterior IC |
| 0.010 | 35 | 4.47 | 32 18 –12 | Right anterior IC |
| Other-pain: controls > placebo | ||||
| 0.023 | 232 | 4.23 | 16 36 18 | aMCC |
| 0.048 | 52 | 4.02 | −8 18 26 | aMCC |
| 0.001 | 41 | 4.75 | −26 30 2 | Left anterior IC |
Notes: (A) Significant clusters resulting from the contrasts (self-unpleasant: control group > placebo group) and (other-unpleasant: control group > placebo group). (B) Significant clusters resulting from the contrasts (self-pain: control group > placebo group) and (other-pain: control group > placebo group) (small-volume-corrected P < 0.05; k = cluster size, MNI = Montreal Neurological Institute stereotactic space).